Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Internal Medicine | Nephrology | Nursing | Journal

Back to Journal Articles

In CKD, Fish Oil Doesn’t Up Hemodialysis Graft Patency

Last Updated: May 01, 2012.

 

Lower graft failure, secondary cardiovascular benefits seen in stage 5 chronic kidney disease

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with stage 5 chronic kidney disease, fish oil does not improve synthetic hemodialysis graft patency, according to a study published in the May 2 issue of the Journal of the American Medical Association.

TUESDAY, May 1 (HealthDay News) -- For patients with stage 5 chronic kidney disease, fish oil does not improve synthetic hemodialysis graft patency, according to a study published in the May 2 issue of the Journal of the American Medical Association.

Charmaine E. Lok, M.D., from the University of Toronto and Toronto General Hospital, and colleagues investigated the effect of fish oil on synthetic hemodialysis graft patency in 201 adults with stage 5 chronic kidney disease. Participants from the Fish Oil Inhibition of Stenosis in Hemodialysis Grafts study were randomized to receive fish oil capsules (four 1-g capsules/day) or matching placebo on day seven after graft creation, and were followed for 12 months. The primary outcome was the proportion of patients experiencing graft thrombolysis or radiological or surgical intervention during follow-up.

The researchers found that graft patency did not differ between the fish oil and placebo groups (48 and 62 percent, respectively; relative risk, 0.78). In the fish oil group, the rate of graft failure was significantly lower (3.43 versus 5.95 per 1,000 access-days; incidence rate ratio [IRR], 0.58). In addition, there were significantly fewer thromboses (1.71 versus 3.41 per 1,000 access-days; IRR, 0.50), fewer corrective interventions (2.89 versus 4.92 per 1,000 access-days; IRR, 0.59), improved cardiovascular event-free survival (hazard ratio, 0.43), and lower mean systolic blood pressure (−3.61 versus 4.49 mm Hg) in the fish oil group.

"Among patients with new hemodialysis grafts, daily fish oil ingestion did not decrease the proportion of grafts with loss of native patency within 12 months," the authors write.

Several of the authors disclosed financial ties to the medical technology and pharmaceutical industries.

Abstract
Full Text
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Methodological Heterogeneity Seen in Clinical Trials Next: Elelyso Approved for Type 1 Gaucher Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.